CompletedNCT05494437
PP-01 medicine study for cannabis withdrawal symptoms
About this title
Read the official source — NCT05494437Medication studyAges 18–55United StatesAddiction
Understand this study
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- Glendale and 17 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: October 27, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 234
- Sponsor
- PleoPharma, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Combination product, Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT05494437
- Official title
Show the full official title
A Phase 2, Multicenter, Randomized, Double-Blind, Multiple-Dose, Placebo Controlled Clinical Trial of Two Doses of PP-01 for the Mitigation of Cannabis Withdrawal Symptoms
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Glendale · Lemon Grove · Orange
15 more locations
- Coral Springs
- Fort Myers
- Lauderhill
- Decatur
- Savannah
- Chicago
- Edgewood
- Marrero
- Shreveport
- Berlin
- Middleburg Heights
- Oklahoma City
- Charleston
- Austin
- Draper
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is PleoPharma, Inc.
Did this study involve medication?
Yes. The study involved medication, including Placebo, Nabilone and Gabapentin.
Who was this study for?
Listed age limits: 18 years to 55 years.
